Table 1.
Demographic, clinical, and treatment characteristics of study patients at study entry (n = 15).
| Age (years) | 43 (33–51) |
| Gender (M/F), n | 14/1 |
| MSM/HTS, n | 14/1 |
| Time since HIV-1 acquisition to ART (days) | 92 (28–164) |
| Pre ART log10 HIV-1 RNA (copies/ml) | 4.9 (3.2–5.8) |
| Time on ART (years) | 3.23 (3.03–3.77) |
| ART regimen, n (%) | |
| TDF/FTC/RAL | 11 (73) |
| ABC/3TC/RAL | 2 (13) |
| ABC/3TC/DTG | 2 (13) |
| CD4+ T-cell counts (cells/mm3) | 728 (416–1,408) |
| Ratio CD4/CD8 | 1.37 (0.97–1.93) |
Median (range) is shown unless otherwise described. M, male; F, female; MSM, men who have sex with men; HTS, heterosexual; ART, antiretroviral therapy; TDF, Tenofovir Disoproxil Fumarate; FTC, Emtricitabine; RAL, Raltegravir; ABC, Abacavir; 3TC, Lamivudine; DTG, Dolutegravir.